340B, Eli Lilly

Eli Lilly follows J&J in suing Biden administration over 340B rebates
Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead of giving them upfront discounts on 340B drugs.
Eli Lilly follows JNJ in suing govt. over 340B drug-discount program
Eli Lilly (NYSE:LLY) has filed a lawsuit over a U.S. health agency's alleged attempts to block its model for offering rebates for drugs supplied under the government's 340B Program, days after its rival Johnson & Johnson (NYSE:JNJ) filed a similar lawsuit.
J&J sues HRSA for blocking controversial 340B rebate plan
Johnson & Johnson is escalating its fight with the federal government over its controversial plan to change how it doles out drug discounts to hospitals. | Johnson & Johnson is escalating its fight with the federal government over its controversial plan to change how it doles out drug discounts to hospitals.
Lilly sues US agency over blocking of drug-rebate program
Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking the company's plan to change the way it offers drug discounts to hospitals.
Eli Lilly sues to change hospital drug discount payments, WSJ reports
Eli Lilly (LLY) has filed a lawsuit against the heads of the Department of Health and Human Services and one of its agencies, seeking a court
Lilly Sues U.S. to Change Hospital Drug Discount Payments
Eli Lilly sued a federal health agency that has blocked the company’s plan to tighten the way it provides lucrative drug discounts to hospitals.Lilly is the second drugmaker this week to go to court over the issue,
Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program
Key Takeaways Eli Lilly has joined Johnson & Johnson in filing a lawsuit against the federal government over a decades-old drug discounting program.The companies have said the 340B program, which requires drugmakers to sell discounted medications to certain medical facilities,
Becker's Hospital Review2h
Drugmakers' 340B rebate fight, explained
Johnson & Johnson and Eli Lilly both sued the federal government this month over the future of their respective 340B drug rebate plans.
Is The Time Right For Congressional Action On 340B?
The aims of the 340B program are important. But, unfortunately, there is little evidence that the program is delivering on ...
Modern Healthcare4d
How lawsuits may reshape 340B reimbursement
Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...
Healthcare Dive5d
J&J sues federal government for halting 340B rebate plan
The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...
HHS Must End Unauthorized Administration Of 340B Drug-Discount Program
Despite rebukes by two federal circuit courts, an HHS sub-agency continues to overstep its authority when administering a ...
Modern Healthcare3d
340B drug rebate proposal leads to another lawsuit
Eli Lilly contends it should be allowed to vet data from 340B hospitals before providing rebates, rather than offer upfront ...
STAT3d
Pharmalittle: We’re reading about an Alzheimer’s drug about-face, Bavarian Nordic’s views on Trump, and more
Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
The Gazette5d
Experts say federal drug pricing program has been abused, misused
During a breakfast hosted by Colorado Politics in Downtown Denver on Tuesday, a panel discussed the state and national ...
JD Supra4d
California Votes to Impose 340B Spending Restrictions on Targeted 340B Providers
California is poised to pass a ballot measure aimed at imposing 340B spending restrictions for certain healthcare entities participating in the ...